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Abstract
Background: Palliative pemetrexed-based chemotherapy remains a standard of care treatment for the majority of
patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Currently, no predictive markers for
pemetrexed treatment are available.
Methods: Resected tumour samples from pemetrexed-naïve NSCLC patients were collected. Gene expression
profiling with respect to predicted sensitivity to pemetrexed classified predicted responders (60%) and non-
responders (40%) based on differentially expressed genes encoding for pemetrexed target enzymes. Genes
showing a strong correlation with these target genes were selected for measurement of corresponding protein
expressions by immunohistochemical (IHC) staining. A semi-quantitative IHC scoring method was applied to construct
a prediction model for response to pemetrexed. A retrospective cohort of patients with advanced NSCLC treated with
first-line pemetrexed-based chemotherapy was used for external validation.
Results: From ninety-one patients resected tumour samples were collected. The majority of patients had early or
locally advanced NSCLC (96.3%). Gene expression profiling revealed five markers, which mRNA levels strongly
correlated to pemetrexed target genes mRNA levels: TPX2, CPA3, EZH2, MCM2 and TOP2A. Of 63 (69%) patients
IHC staining scores of these markers were obtained, which significantly differed between predicted non-responders
and responders (P < 0.05). The optimized prediction model included EZH2 (OR = 0.56, 95% CI 0.35–0.90) and TPX2
(OR = 0.55, 95% CI 0.30–1.01). The model had a sensitivity of 86.8%, specificity of 63.6% and showed a good
ability to distinct between responders and non-responders (C-index 0.86).
In the external study population (N = 23) the majority of patients had metastatic NSCLC (95.7%). Partial response
(PR) was established in 26.1%. The sensitivity decreased drastically to 33.3%, with a specificity of 82.4% and a
C-index of 0.73.
Conclusions: Using external validation this prediction model with IHC staining of target enzyme correlated
markers showed a good discrimination, but lacked sensitivity. The role of IHC markers as response predictors
for pemetrexed in clinical practice remains questionable.
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Background
In the management of advanced non-small cell lung can-
cer (NSCLC) systemic treatment options are rapidly
expanding with the increasing use of molecular targeted
agents and immunotherapy [1–4]. One of the most im-
portant therapeutic advances has been the identification
of predictive molecular markers to guide patient selec-
tion for frontline treatment with these agents, like sensi-
tizing mutations within the EGFR gene to EGFR tyrosine
kinase inhibitors and protein PD-L1 overexpression to
anti PD-(L)1 checkpoint inhibitors [1, 2, 5]. Despite
the changing treatment landscape with increasing use
of molecular targeted agents and immunotherapy,
pemetrexed-based chemotherapy is still widely used
as standard treatment in patients with advanced non-
squamous non-small-cell lung cancer [6, 7]. Unfortu-
nately, to date useful biomarkers predicting response
to this treatment regimen are lacking.
Pemetrexed treatment shows a variable clinical efficacy
apparently dependent on the histologic subtype of lung
cancer. Clinical trials demonstrated efficacy of peme-
trexed in nonsquamous NSCLC while efficacy was worse
in squamous NSCLC and small-cell lung cancer [8–10].
However, tumour response to pemetrexed also differs
significantly between patients with similar histology
[9, 11]. In patients treated with pemetrexed mono-
therapy, the response rate to pemetrexed was evi-
dently different between histological subtypes but low
in both patients with squamous and non-squamous
NSCLC (2.8% vs. 11.5%) [10]. In this study peme-
trexed was administered as second-line treatment and
patients with poor ECOG performance score were in-
cluded. Although the response rate to pemetrexed was
significantly higher in patients with non-squamous versus
squamous NSCLC in the first-line pivotal trial [9], still
more than 20% of patients with squamous NSCLC had a
response to pemetrexed while the response rate was
merely ~ 30% in patients with non-squamous histology
[11]. These findings highlight the need for predictive mo-
lecular markers for pemetrexed-based treatment.
The main determinant of pemetrexed responsiveness is
thought to be the level of expression of thymidylate synthase
(TS), the primary intracellular target enzyme of pemetrexed
[12, 13]. Overexpression of TS mRNA has been correlated
with reduced sensitivity to pemetrexed in vitro, [14–17] and
with worse clinical outcomes in patients treated with peme-
trexed [18]. Moreover, the abundance of TS expression is
higher in squamous cell NSCLC than in other histologic sub-
types, [19, 20] which constitutes the biological hypothesis be-
hind the superior efficacy of pemetrexed in non-squamous
NSCLC. However, in clinical practice the relationship be-
tween protein expression levels of TS, measured by immuno-
histochemistry (IHC) methods, and the clinical efficacy of
pemetrexed remains controversial [21–25].
Our study group earlier presented an approach to im-
plement a more refined molecular classification of
NSCLC subtypes based on gene expression profiles inde-
pendent of histology [26]. Furthermore, response to
pemetrexed was predicted based on expression of genes
encoding different pemetrexed target enzymes including
but not limited to TS, and expression signatures of cor-
related genes were identified. In the current study, we
explore whether these differential gene expression pro-
files between responders and non-responders can be
used to define a prediction model based on IHC scores
of selected molecular markers.
Methods
Training cohort
Tumour samples from pemetrexed-naïve, NSCLC pa-
tients who had undergone curative surgical resection at
the Erasmus Medical Center (Rotterdam) between 1992
and 2004 were used. A detailed description of tissue col-
lection, microarray preparation and data processing, the
derivation of a gene-expression based predictive algo-
rithm for tumour response and the identification of
pemetrexed resistance-associated genes has been previ-
ously described [26]. In short, the predictive algorithm
predicted tumour response based on the expression dif-
ference between internal reference genes and peme-
trexed target genes TS, dihydrofolate reductase (DHFR)
and glycinamide ribonucleotide formyltransferase (GARFT).
Using percentile-rank based target gene expression levels
relative to the internal reference genes, patients were strati-
fied as predicted responders (±60%) and non-responders
(±40%). Subsequently, significance analysis of microarray
identified differentially expressed genes between these classi-
fied groups [27]. A minimized signature containing 25 genes
performed optimally in predicting pemetrexed response
(Additional file 1: Table S1). For the current study, we se-
lected molecular markers from this signature if they showed
a strong correlation with the gene expression of TS and if
IHC stainings for these markers were commercially avail-
able. Written informed consent was obtained from all these
patients. The study was conducted in accordance with the
REMARK guidelines [28].
Validation cohort
In order to externally validate the model, we obtained
formalin-fixed paraffin-embedded pre-treatment biopsies
of a retrospective cohort of patients newly diagnosed
with advanced stage (IIIB/IV) NSCLC in a large teaching
hospital (Amphia hospital, Breda, the Netherlands) be-
tween January 2007 and December 2010. Patients were
eligible for enrolment if they had received ≥2 cycles of
platinum-combined pemetrexed chemotherapy as first-line
treatment. Medical charts and radiological imaging
data were reviewed to collect information regarding
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socio demographics, tumour histology, ECOG perform-
ance status, treatment and observed tumour response
(RECIST 1.1). Patients with early stage (IA-IIB) or locally
advanced (IIIA) disease, (neo)adjuvant chemotherapy,
combination treatment with bevacizumab and without tis-
sue samples from primary tumour or (lymph node) metas-
tasis were excluded.
Tissue microarray analysis and immunohistochemistry
The tissue microarrays (TMAs) were composed of 68 of
the 91 tumour tissues, in triplicate, from the Erasmus
MC patient cohort used for the expression microarray
analyses. TMA blocks containing 0.6 mm cores of
formalin-fixed paraffin-embedded tumours were cut and
antigen retrieval was performed by a 20-min incubation
at 95 °C using Trisethylenediaminetetraacetic acid buffer
(Klinipath, Duiven, The Netherlands). Subsequently,
TMAs were stained with primary antihuman antibodies
of the selected candidate markers: EZH2, TOP2A, TPX2,
MCM2 and CPA3 (Additional file 2: Table S2). For each
TMA multicontrol stainings were performed using a
combination of tissues (liver, pancreas, tonsil, colon and
appendix). The slides were stained and processed in the
Ventana Benchmark ULTRA strainers, using DAB as
substrate and Hematoxylin as counterstain. Tumour tis-
sues from the validation group were equally handled, ex-
cept that the tumour samples were cut in 0.4 mm
instead of 0.6 mm cores for TMA blocks.
Immunohistochemical staining score
A semi-quantitative scoring method was applied to clas-
sify the intensity and quantity of IHC staining of candi-
date markers. The quantity score was defined as: 1: 0–
30%; 2: 30–60%; 3: 60–100%. The intensity score was de-
fined as: 0 (negative), no appreciable staining in the
tumour cells; 1 (weak), barely detectable cytoplasmic/
membranous or nuclear staining of tumour cells; 2
(moderate), readily appreciable staining of tumour cyto-
plasm/nucleus; 3 (strong), strong staining obscuring nu-
cleus/cytoplasm of tumour cells. Multiplying quantity
and intensity score yielded a total score with a range be-
tween 0 and 9. TMAs from the training group were eval-
uated and scored for protein expression simultaneously
by K.B. and J.P.H. Samples were individually discussed
until consensus was reached. For the validation group,
TMA evaluation and protein staining quantification
were performed independently by K.B. and S.V.
Statistical analyses
Sociodemographic and disease- and treatment-related
variables were described for all patients who were in-
cluded in this study and were compared between the
training and validation group. We used the independent-
samples t-test and the χ2-test or Fisher’s exact test for
continuous and categorical variables respectively. Degree
of agreement on quantity and intensity scores of the dif-
ferent IHC stainings was evaluated using weighted linear
Cohen’s kappa scores ( ) in the validation group. De-
gree of agreement was determined according to widely
used scale described by Landis and Koch [29]. As IHC
staining scores from the training group were obtained by
discussion, and thus not independently, no interobserver
agreement could be calculated.
Pearson correlation coefficients (ρ) were calculated be-
tween gene expression of the candidate markers and TS
in the training group and subsequently between the gene
expression of those markers and their associated protein
expressions. Using the described prediction algorithm of
response to pemetrexed, patients from the training group
were divided in predicted responders and non-responders.
In the training group, we compared gene and protein ex-
pression from selected molecular markers between pre-
dicted responders and non-responders.
Logistic regression with dependent variable predicted
tumour response by gene expression signature was ap-
plied to the training cohort to build a prediction model
with the IHC staining scores of selected molecular
markers as independent variables. Optimized model der-
ivation was performed using purposeful selection by
stepwise in- and exclusion of molecular markers [30].
Univariable logistic regression identified molecular
markers associated with predicted tumour response. We
specified a priori that molecular markers with p < 0.2 on
univariable analysis would be candidate variables for
multivariable logistic regression model. In the iterative
process of variable selection, variables were removed
from the model if they were non-significant and not a
confounder. We used backward selection with a p-value
< 0.05 and/or change of effect size of (an)other included
variable(s) > 20% to remain in the model. The fit of a re-
duced model versus full model was compared with the
likelihood ratio test (LRT), following a chi-squared dis-
tribution. Subsequently, the model was externally vali-
dated in the validation cohort. In both cohorts, the
model performance of the derived model was assessed
by examining the predictive classification accuracy and
discriminatory ability (C-index). A C-index of 1.0 would
indicate perfect discrimination, whereas a C-index of 0.5
indicates total absence of discrimination. All statistical
analyses were performed with the use of SPSS, version
24.0 (IBM Corporation, Armonk, NY).
Results
The selection of patients in both training and validation
cohort is depicted in Fig. 1. Of the 91 surgically resected
samples of the primary tumour, 68 (74.7%) samples were
suitable for further processing into TMAs. Since samples
of five patients could not be used due to insufficient
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TMA material, the training cohort ultimately consisted
of 63 patients whose samples were prepared with add-
itional IHC stainings. For validation, 44 of 142 (31%) pa-
tients who received pemetrexed had advanced stage
NSCLC treated with ≥2 cycles first-line treatment with
platinum-combined pemetrexed, excluding combinations
with bevacizumab. Of these patients, 18 (40.9%) were ex-
cluded from further analysis because their diagnosis was
cytology-based and no histologic biopsy was obtained.
Histology samples were retrieved from primary tumour
(N = 13) or lymph nodes or distant metastases (N = 13).
Three patients had insufficient tumour material available
for additional IHC staining and therefore the validation
cohort consisted of 23 patients.
Patient characteristics
Patient and treatment characteristics are shown in
Table 1. In the training cohort 46 patients (73.0%) were
male compared to 10 (43.5%) in the validation cohort.
Eighteen patients (28.6%) had squamous NSCLC in the
training cohort while in the validation cohort only pa-
tients were included with non-squamous histology. The
majority of patients (95.2%) in the training group had
early stage NSCLC opposed to all patients with advanced
disease stage in the validation group. No data were avail-
able with regard to the ECOG performance score of the
patients in the training cohort. In the validation cohort,
21.7% of the patients had a performance score of 2. Corre-
sponding to the differences in disease stage between the
cohorts, all patients in the training cohort underwent sur-
gical resection in contrast to palliative pemetrexed-based
chemotherapy in the validation cohort. Patients in the
training cohort had worse overall survival compared to
the validation cohort (4.5months vs. 28months).
Selection molecular markers
Of the 25-genes containing optimized gene expression
signature predicting response to pemetrexed in the
Fig. 1 Flowchart of training and validation population. Abbreviations: NSCLC, non-small-cell lung cancer; TMA, tissue micro array; IHC, immunohistochemical
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training group, five molecular markers were selected
based on their correlation with the gene expression level
of target genes (TS, DHFR, GARFT) and the commercial
availability of corresponding IHC stainings: Enhancer of
zeste homolog 2 (EZH2), Topoisomerase II Alpha
(TOP2A), Microtubule Nucleation Factor (TPX2), Car-
boxypeptidase A3 (CPA3) and Minichromosome Main-
tenance Complex Component 2 (MCM2). All markers
showed a positive correlation to the mRNA level of TS
(EZH2, ρ = 0.732; MCM2, ρ = 0.804; TOP2A, ρ = 0.814;
TPX2, ρ = 0.825), except for CPA3 which was negatively
correlated (ρ = − 0.467) (Additional file 4: Figure S1). The
correlation of gene mRNA level with their corresponding
IHC staining score had a range between 0.303 (CPA3) and
0.578 (EZH2) (Additional file 5: Figure S2).
The IHC stainings of the same markers were applied
to the TMAs of the samples of patients in the validation
cohort. The strength of agreement between the observers
with regard to the intensity score ranged between 휅 =
0.515 (CPA3) and휅 = 1 (MCM2), and with regard to the
quantity score between휅 = 0.547 (TPX2) and휅 = 0.851
(CPA3). Weighted kappa values of IHC staining scores are
outlined in Additional file 3: Table S3.
Of all selected markers, both mRNA levels and IHC
staining scores were significantly higher in predicted
non-responders than responders in the training group,
except for CPA which mRNA level and IHC staining
score was significantly lower in non-responders com-
pared to responders. These results are depicted in Fig. 2.
Model derivation
The model coefficients and odds ratios (OR) with corre-
sponding 95% confidence intervals (CI) of the prediction
model with dependent variable tumour response to
pemetrexed using univariable and multivariable logistic
regression analyses are presented in Table 2. Univariable
analyses of the relationship between the IHC staining
scores of the selected markers and the gene expression
based predicted tumour response to pemetrexed were
performed using the training cohort. Higher IHC stain-
ing scores of all markers were significantly associated
with worse predicted tumour response, except for CPA3
which repeatedly showed the reverse association com-
pared to the other markers. Using multivariable analysis,
only a higher IHC staining score of EZH2 was signifi-
cantly related with a worse predicted tumour response
to pemetrexed (OR 0.56, 95% CI 0.35–0.90; P = 0.015).
The staining scores of all other markers failed to demon-
strate a significant association on multivariable analysis.
Although IHC staining score of TPX2 was not signifi-
cantly associated with tumour response in the multivari-
able model (OR 0.55, 95% CI 0.30–1.01; P = 0.054), this
variable was still included in the final optimized predic-
tion model. Removal of this variable led to a significantly
reduced model fit (P < 0.001).
Model performance and validation
In Table 3 the different test characteristics describing the
performance of the model in the training and validation
cohort are shown. In the training cohort, 38 patients were
predicted responders (63.3%) by gene expression profiling
and 86.8% (33 of 38) were correctly classified responders
by the prediction model (sensitivity 86.8%, 95% CI 71.9–
95.6). Fourteen patients were predicted non-responders
Table 1 Characteristics of patients in the training population
and the validation population
Training cohort
(N = 63)
Validation cohort
(N = 23)
Age, mean (SD) 61.9 (±10.7) 58.7 (±8.7)
Gender, male 46 (73.0) 10 (43.5)
Smoking status
Never smoker 1 (1.6) 1 (4.3)
Ever smoker 31 (49.2) 21 (91.3)
Unknown 31 (49.2) 1 (4.3)
ECOG performance score
0 or 1 17 (73.9)
2 5 (21.7)
Unknown 63 (100) 1 (4.3)
Histology
ADC 18 (28.6) 21 (91.3)
LCC 24 (38.1) 2 (8.7)
SCC 15 (23.8)
Other 6 (9.5)
Tumor stage
IA-IIB 56 (88.9)
IIIA 4 (6.3)
IIIB 1 (4.3)
IV 3 (4.8) 22 (95.7)
Treatment
Surgery 63 (100)
CISPEM 18 (78.3)
CARPEM 5 (21.7)
No. cycles chemotherapy,
median (IQR)
3 (3–4)
Treatment effect
PR 6 (26.1)
SD 7 (30.4)
PD 10 (43.5)
OS, median (IQR) 28.0 (10.0–67.6) 4.5 (3.2–7.3)
Data are expressed as numbers (%) unless stated otherwise. Abbreviations: SD
standard deviation, ADC adenocarcinoma, LCC large cell carcinoma, SCC
squamous cell carcinoma, CISPEM cisplatin combined with pemetrexed, CARPEM
carboplatin combined with pemetrexed, OS overall survival, IQR interquartile
range, PR partial response, SD stable disease, PD progressive disease
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(36.7%) by gene expression profiling while 63.6% (14 of
22) were correctly classified as non-responders by the
model (specificity 63.6%, 95% CI 40.7–82.8).
In the validation cohort, the same classification by the
prediction model was applied, however an actual tumour
response was obtained as these patients were treated
with pemetrexed. The response rate was 26.1% and
therefore the prevalence of response was substantially
lower than in the training cohort. Of the six patients
who experienced a partial response, two patients were
correctly classified by the prediction model resulting in a
sensitivity of 33.3% (95% CI 4.3–77.7). Herewith, the
sensitivity in this cohort is significantly worse than the
sensitivity in the training cohort (Fisher’s exact test, P =
0.011). The positive predictive value (PPV) also de-
creased substantially. If we classified both patients with
a partial response and stable disease as responders
(56.5%), performance characteristics of the model de-
clined dramatically (Table 3).
The ROC curve showed a C-index of 0.86 (95% CI
0.77–0.96) in the training cohort, representing a good
discriminatory performance. The C-index decreased to
0.73 (95% CI 0.52–0.93) if the prediction model was ap-
plied to the validation cohort (Fig. 3).
Discussion
Currently, the profit of and need for molecular markers
to select therapy for individual patients is increasingly
recognized. The last several years, treatment of advanced
NSCLC has become obviously more complex and there-
fore tools to choose therapies that are most likely to
benefit patients are required. Indeed the registration of
Fig. 2 Boxplots of gene and protein expression levels of selected markers in predicted responders and non-responders to pemetrexed in the
training group. Boxplots (Tukey) representing medians and interquartile ranges of relative mRNA expression and IHC staining scores
respectively. Whiskers represent minimum and maximum 1.5 interquartile range and dots are outliers. Abbreviations: IHC,
immunohistochemical; EZH2, Enhancer of zeste homolog; TOP2A, Topoisomerase II; TPX2, Microtubule Nucleation Factor; CPA3,
Carboxypeptidase A3; MCM2, Minichromosome Maintenance Complex Component 2. Abbreviations: IHC, immunohistochemical; EZH2, Enhancer of
zeste homolog; TOP2A, Topoisomerase II Alpha; TPX2, Microtubule Nucleation Factor; CPA3, Carboxypeptidase A3; MCM2, Minichromosome
Maintenance Complex Component 2
Table 2 Prediction model derivation to predict tumor response using IHC staining scores of selected molecular markers in training
group (N = 63)
Univariable analysis Optimized model
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
IHC score CPA3 1.82 (1.08–3.07) 0.025
IHC score EHZ2 0.47 (0.30–0.71) < 0.001 0.56 (0.35–0.90) 0.015
IHC score TPX2 0.43 (0.26–0.70) 0.001 0.55 (0.30–1.01) 0.054*
IHC score MCM2 0.75 (0.0.59–0.96) 0.022
IHC score TOP2a 0.67 (0.51–0.88) 0.003
*Model fit was significantly worse (based on difference − 2 Log Likelihood) if TPX2 was excluded. Abbreviations: CI confidence interval, EZH2 Enhancer of zeste
homolog, TOP2A Topoisomerase II Alpha, TPX2 Microtubule Nucleation Factor, CPA3 Carboxypeptidase A3, MCM2 Minichromosome Maintenance Complex
Component 2
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new therapeutic agents as frontline therapy is accom-
panied by selective markers. For patients with EGFR
mutation-positive, ALK rearrangement-positive or ROS1
rearrangement positive tumours first-line molecular tar-
geted tyrosine kinase inhibitors are recommended, while
patients with high PD-L1 expression in the tumour are
suitable for pembrolizumab first-line treatment [6]. Des-
pite the wide implementation of molecular markers, the
administration of chemotherapy in NSCLC patients is
still solely based on histology even though its capacity to
predict response has been proved to be suboptimal.
In an earlier study, we demonstrated an approach to
predict response to pemetrexed based on the use of gene
expression profiles [26]. Samples of different histological
subtypes including squamous NSCLC were used. Predic-
tion of response to pemetrexed based on gene expres-
sion profiling of its target enzymes, failed to show the
expected disadvantage for the squamous cell histological
subtype and these results therefore challenge the re-
stricted use of pemetrexed in non-squamous NSCLC. In
the present study, we developed a prediction model
using immunohistochemistry scores of selected
candidate genes (EZH2 and TPX2) from the gene ex-
pression signature predicting pemetrexed response. In
the training group, the use of the model resulted in good
performance characteristics of the model in the sense of
a high sensitivity and PPV. The model also showed the
ability to discriminate well between responders and
non-responders. Unfortunately, the results of the ob-
tained model could not be validated when applied to an
external cohort of patients treated with pemetrexed.
Although it is hypothesized that superior efficacy of
pemetrexed in non-squamous over squamous NSCLC is re-
lated to the level of TS expression, multiple clinical studies
failed to demonstrate the association between TS protein
expression and clinical outcomes [22, 25]. This can be as-
cribed firstly to the fact that current semi-quantitative IHC
methods might lack sensitivity required to measure protein
expression of TS opposed to quantitative analysis of mRNA
expression. And secondly, the biological significance of TS
for pemetrexed responsiveness might be of less importance
than other molecular processes, e.g. gene expression or
amplification of other (target) genes. To overcome these
limitations in the present study, we carefully selected
Table 3 Conditional and post-test probability performance of the IHC based prediction model in the training and validation cohort
Training cohort Validation cohort Responder: PR Validation cohort Responder: PR + SD
Prevalence (responder) 63.3 (49.9–75.4) 26.1 (10.2–48.4) 56.5 (34.5–76.8)
Sensitivity 86.8 (71.9–95.6) 33.3 (4.3–77.7) 15.4 (1.9–45.5)
Specificity 63.6 (40.7–82.8) 82.4 (56.6–96-2) 70.0 (34.6–93.3)
LR+ (weighted by prevalence) 2.39 (1.36–4.21) 1.89 (0.41–8.71) 0.51 (0.10–2.51)
LR- (weighted by prevalence) 0.21 (0.09–0.50) 0.81 (0.44–1.49) 1.21 (0.76–1.93)
PPV 80.5 (70.1–87.9) 40.0 (12.6–75.5) 40.0 (12.0–76.5)
NPV 73.7 (53.8–87.1) 77.8 (65.6–86.5) 38.9 (28.5–50.4)
Data are expressed as percentages, except LR+ and LR- (odds), with 95% confidence intervals. Abbreviations: LR+ positive likelihood ratio, LR- negative likelihood
ratio, PPV positive predictive value, NPV negative predictive value
Fig. 3 Receiver operating characteristic curve showing model performance of two-protein expression prediction model in training and validation
population. Diagonal line reflects total absence of discrimination (AUC = 0.5). Abbreviations: AUC, area under the curve
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markers related to mRNA gene expression of TS but also
to other target enzymes DHFR and GARFT.
In the literature, both EZH2 and TPX2 have been pre-
viously linked to survival in NSCLC. TPX2 is involved in
key steps during mitotic events and increased expression
has been associated with poor overall survival in NSCLC
[31, 32]. EZH2 epigenetically silences multiple genes in-
volved in cell differentiation, growth and invasion. It is
often overexpressed in NSCLC promoting cancer
progression and a more aggressive tumour behaviour
[33, 34]. Downregulation of EZH2 has been associated
with higher expression of oestrogen receptor and in-
creased sensitivity to tamoxifen in advanced breast can-
cer patients [35]. Similarly, one can speculate that EZH2
might change the expression of genes related to respon-
siveness of pemetrexed through its ability to silence
other genes. Although lack of a control arm precludes
discrimination between a prognostic or predictive factor,
we purposefully focused on radiological response rather
than survival.
It is crucial to predict treatment effects for individual
patients in order to avoid unnecessary toxicities and to
offer alternative treatment options, with few false posi-
tives [36]. The clinical value of the derived model is
probably limited as the sensitivity was poor in the valid-
ation group. Moreover, the low PPV makes the classifier
not useful for clinical decision making, as many patients
who are predicted responders will then actually undergo
potentially harmful treatment with low chance of
tumour response. The failure of the prediction model to
adequately perform in the external patient population
might be ascribed to an insufficient sensitivity of used
IHC assays to measure significant differences in protein
expression or a discrepancy between protein expression
and protein activity. Additionally, spatiotemporal hetero-
geneity might have led to different intrinsic tumour
properties in the validation group as these patients had
advanced disease and in half of the cases tumour sam-
ples were obtained from lymph node or distant metasta-
ses. Finally, other factors might influence pemetrexed
activity such as cell transport and intracellular formation
of polyglutamate metabolites [37]. Our study was limited
in the number of patients included, especially in the ex-
ternal validation.
cohort. We recognize that the differences in histology
between the training and validation cohort is a major
shortcoming. It was impossible to include patients with
non-squamous NSCLC to the validation cohort, as selec-
tion was treatment-based and pemetrexed is only recom-
mended in patients with nonsquamous NSCLC. For
ALK and ROS1-rearrangement positive adenocarcinoma
patients might experience more benefit to pemetrexed-
based chemotherapy [38, 39], molecular characteristics
would have been desirable. Unfortunately, those data
were not available in our cohort, but the high number of
smokers profoundly reduces the chance of rearrangements.
Although response rates were in accordance with the litera-
ture, patients in the validation cohort experienced a very
poor median overall survival of only 4.5months. This can
be partially explained by the presence of a substantial group
of patients (> 20%) with a poor ECOG performance score
and suboptimal treatment with carboplatin instead of cis-
platin combination. Whether these patients appropriately
represent the population with advanced NSCLC is there-
fore highly questionable and we cannot exclude their gen-
etic profile to be different. However, given the results we do
not expect that expanding the number of samples will lead
to a clinically useful biomarker.
Conclusion
There remains an unmet need to identify biomarkers to
select patients for standard pemetrexed-based treatment.
Prediction of pemetrexed responsiveness with IHC stain-
ings of markers correlated to TS and other target enzymes
could not be validated using external validation. Future re-
search focusing on metabolomics, pharmacokinetics and
pharmacogenetics might offer new insights into tailoring
therapy. Until a well-validated biomarker is identified,
histology should remain the standard to select advanced
NSCLC patients eligible for treatment with pemetrexed.
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